RGLSRegulus Therapeutics Inc
Mkt Cap
$564.95MVolume
9.34M52W High
$8.3552W Low
$0.8301PE Ratio
-11.23RGLS Fundamentals
Price
$8.16Prev Close
$8.14Open
$8.1550D MA
$7.51Beta
1.14Avg. Volume
2.41MEPS (Annual)
-$0.8227P/B
7.84Rev/Employee
$0.00Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference...
PR Newswire·9mo ago
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) Regulus Therapeutics Announces...
PR Newswire·9mo ago
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences PR Newswire SAN...
PR Newswire·11mo ago
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates PR Newswire SAN DIEGO, Nov...
PR Newswire·1y ago
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant...
PR Newswire·1y ago
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire SAN DIEGO, Aug...
PR Newswire·1y ago
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates PR Newswire SAN DIEGO, Aug...
PR Newswire·1y ago
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire SAN DIEGO, July...
PR Newswire·1y ago